PPH - VanEck Vectors Pharmaceutical ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
59.87
-0.12 (-0.20%)
As of 12:15PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close59.99
Open59.98
Bid59.93 x 1100
Ask59.94 x 800
Day's Range59.81 - 60.39
52 Week Range54.56 - 64.90
Volume53,021
Avg. Volume49,934
Net Assets278.45M
NAV62.74
PE Ratio (TTM)N/A
Yield1.64%
YTD Return7.30%
Beta (3Y Monthly)0.86
Expense Ratio (net)0.35%
Inception Date2011-12-20
Trade prices are not sourced from all markets
  • InvestorPlace3 days ago

    Don’t Punish Gilead Stock for Doing Its Job

    In a turbulent year for Gilead Sciences (NASDAQ:GILD), the company recently generated headlines that will hopefully turn things around for GILD stock. Over the weekend, insider information pegged Roche Holdings (OTCMKTS:RHHBY) executive Daniel O’Day as its new CEO. O’Day is no stranger to the industry, having served as Roche Pharmaceuticals’ chief executive since June 3, 2016.

  • GlaxoSmithKline Stock Has Increased ~15% in 2018
    Market Realist23 days ago

    GlaxoSmithKline Stock Has Increased ~15% in 2018

    On November 19, GlaxoSmithKline’s (GSK) stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16. GlaxoSmithKline’s stock price grew from $35.47 when the market closed on December 29, 2017, to $40.83 November 19, which reflects ~15% year-to-date growth.

  • Business Wire27 days ago

    VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

    VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.

  • Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
    Market Realistlast month

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.

  • Assessing GW Pharmaceuticals’ Year-to-Date Performance
    Market Realistlast month

    Assessing GW Pharmaceuticals’ Year-to-Date Performance

    GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.

  • Sanofi’s Q3 Estimates: Expect Revenue Growth
    Market Realistlast month

    Sanofi’s Q3 Estimates: Expect Revenue Growth

    As we discussed earlier, analysts expect Sanofi’s (SNY) revenues to grow 3.3% to 9.3 billion euros during the third quarter. In this part, we’ll discuss Sanofi’s business structure and the estimates for each segment during the third quarter.

  • GlaxoSmithKline’s Q3 2018 Revenue Expected to Grow
    Market Realistlast month

    GlaxoSmithKline’s Q3 2018 Revenue Expected to Grow

    As we saw in the first part of this series, Wall Street analysts expect a 2.5% growth in GlaxoSmithKline’s (GSK) third-quarter revenues to 8.02 billion pounds. The growth could be offset by lower sales of some products and the impact of divestitures.

  • ETF Strategies for the Midterm Elections
    Zacks2 months ago

    ETF Strategies for the Midterm Elections

    Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.

  • How Is Novartis Valued?
    Market Realist2 months ago

    How Is Novartis Valued?

    At constant exchange rates, Novartis (NVS) reported 6% growth in year-over-year revenues to $12,779 million during the third quarter of 2018 as compared to $12,413 million during the third quarter of 2017. Also, foreign exchange had a 2% negative impact on revenues during the quarter.

  • Novartis Reports Third-Quarter Revenue Growth
    Market Realist2 months ago

    Novartis Reports Third-Quarter Revenue Growth

    Novartis (NVS), one of the leading healthcare companies, released its third-quarter earnings on October 18. Novartis surpassed Wall Street analysts’ estimates for EPS but missed estimates for revenues with reported EPS of $1.32 on revenues of ~$12.78 billion as compared to the estimated EPS of $1.31 on revenues of ~$13.02 billion during the third quarter of 2018.

  • A Performance Overview of JNJ’s Beauty and OTC Businesses
    Market Realist2 months ago

    A Performance Overview of JNJ’s Beauty and OTC Businesses

    Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.

  • Business Wire2 months ago

    VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

    ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more

  • Novartis’ Estimates and Recommendations on October 12
    Market Realist2 months ago

    Novartis’ Estimates and Recommendations on October 12

    Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).

  • Novartis: What to Expect from Q3 Earnings on October 18
    Market Realist2 months ago

    Novartis: What to Expect from Q3 Earnings on October 18

    Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.

  • An Update on Bausch + Lomb/International in October
    Market Realist2 months ago

    An Update on Bausch + Lomb/International in October

    Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth. 

  • Investopedia2 months ago

    Top 5 Pharmaceutical ETFs for 2018

    The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.

  • A Look at Novartis’s Valuation on October 9
    Market Realist2 months ago

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.

  • Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
    Zacks2 months ago

    Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

    Sector ETF report for PPH

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist2 months ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Business Wire2 months ago

    Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions

    VanEck announced today its regular distributions per share for the VanEck Vectors® equity exchange-traded funds.

  • Why Bausch Health Stock Is Soaring Today
    Market Realist3 months ago

    Why Bausch Health Stock Is Soaring Today

    Bausch’s current stock price is ~18% lower than the 52-week high of $27.79 it saw on June 13. Bausch hit its 52-week low of $10.94 on November 2, 2017. Today, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and its licensors Cedars-Sinai Medical Center and Alfasigma announced that they’d agreed to resolve pending intellectual property litigation associated with the drug Xifaxan with Actavis Laboratories.

  • Investopedia4 months ago

    Top 5 Pharmaceutical ETFs for 2018

    The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.

  • Merck Witnessed 5% Growth in Q2 2018
    Market Realist5 months ago

    Merck Witnessed 5% Growth in Q2 2018

    Merck (MRK) reported its second-quarter earnings on July 27. Merck generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year (or YoY) growth. In the second quarter, Merck’s Pharmaceuticals segment generated revenues of $9.3 billion compared to $8.8 billion in the second quarter of 2017, reflecting ~6.0% YoY growth. Merck’s Animal Health segment generated revenues of $1.1 billion in the second quarter, reflecting ~14.0% YoY growth.

  • ETF Trends5 months ago

    July Could Be a Volatile Month for Pharma ETFs

    Changing political winds and the seasonal period for drugmakers to hike their prices could trigger short-term volatility in pharmaceutical sector-related ETFs. The markets could put a spotlight on pharmaceutical stocks and the rising cost of drug prices as Mid-term elections are quickly coming up in November and July is a popular month for drug companies to increase list prices on medicines, writes Charley Grant for the Wall Street Journal. Just last week, Health and Human Services Secretary Alex Azar said in congressional testimony that companies should “practice restraint” with price increases.

  • Business Wire5 months ago

    Announcing VanEck Vectors Equity ETFs June 2018 Distributions

    VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds.